The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Zika Virus NS1 Proteins (Uganda/Suriname Strains Duo Pack)

$1,180.81$4,508.50 excl. VAT

Recombinant Zika Virus NS1 protein, with C-terminal 6xHis tags, produced in mammalian HEK293 ells. One vial each of Zika NS1 from Suriname and Uganda strains.

Citations Available


SKU: ZIKVDUO-NS1 Categories: ,


Zika virus NS1 protein 1 (Non-Structural protein 1) has been manufactured in response to the unmet need for highly purified, concentrated protein for use in serological based diagnostic assays. Zika virus NS1 protein is engineered in human cells using state-of-the-art expression and purification techniques.

Each pack contains:

  • 1 vial of ZIKV-NS1 from strain Uganda MR766.
  • 1 vial of ZIKVSU-NS1 from strain Suriname Z110603.

Zika virus NS1 proteins have been produced to the same standards as other Native Antigen Company NS1 proteins, and are presented as highly purified liquid proteins.



Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since spread to South Asia and more recently to South America. It is a member of the flavivirus family, and is structurally closely related to viruses such as Dengue Fever Virus. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections. The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly.

Clinically Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus.

Analysis of Zika virus sequences from infected patients have shown that the strain circulating in South America in 2015 is most closely related to the strains circulating in Asia during outbreaks in 2007 and 2013-14. The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain. The Zika virus NS1 protein in the Suriname strain differs slightly from that in the “original” strain isolated in Uganda in 1947. The Native Antigen Company are pleased to make available Zika Virus NS1 protein from both the Suriname and Uganda strains, enabling researchers to carefully study the differences between the two antigens and the host response to them. The combination pack offers a price advantage in comparison to purchasing the antigens separately.

Certificate of analysis
Safety Datasheet

Publishing research using our reagents? Please let us know so that we can cite your publication as a reference.

  • Rodriguez-Barraquer et al. (2019). Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. Feb 363(6427);607-610. PMID: 30733412
  • Whitehead and Pierson (2019). Effects of Dengue Immunity on Zika Virus Infection. Nature News and Views. Nature 567, 467-468 (2019). PMID: 30911157
  • Balmaseda A et al. (2018). Comparison of four serological methods and two RT-PCR assays for diagnosis and surveillance of Zika. J Clin Microbiol. Jan 5. pii: JCM.01785-17. doi: 10.1128/JCM.01785-17. [Epub ahead of print]. PMID: 29305550
  • Theillet G et al. (2018). Laser-cut paper-based device for the detection of dengue non-structural NS1 protein and specific IgM in human samples. Arch Virol. 2018 Jul;163(7):1757-1767. PMID: 29525973
  • Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018 Mar 19;257:48-57. PMID: 2956751
  • Afsahi S et al (2018). Novel graphene-based biosensor for early detection of Zika virus infection. Biosens Bioelectron. 100:85-88. PMID: 28865242
  • Balmaseda A et al (2017). Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci U S A. Aug 1;114(31):8384-8389. PMID: 28716913
  • Zhang B et al (2017). Diagnosis of Zika virus infection on a nanotechnology platform. Nat Med. May;23(5):548-550. PMID: 28263312
  • Bedin F et al (2017). Paper-based point-of-care testing for cost-effective diagnosis of acute flavivirus infections. J Med Virol. Sep;89(9):1520-1527. PMID: 28295400
  • Conde JN et al (2016). Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. J Virol. Oct 14;90(21):9570-9581. PMID: 27512066